The association between tic medication therapy and psychiatric comorbidities among patients with Tourette syndrome: A national population-based study in Taiwan

Tourette syndrome (TS) is often comorbid with attention deficit hyperactivity disorder, obsessive–compulsive disorder, and depression. Medications are the main treatment for TS. Relationships between TS medication therapy and psychiatric comorbidities remain unclear. This study explored the impacts...

Full description

Saved in:
Bibliographic Details
Published in:Brain & development (Tokyo. 1979) 2020-05, Vol.42 (5), p.373-382
Main Authors: Chen, Chia-Wen, Hsueh, Chang-Wei, Chung, Chi-Hsiang, Wang, Huei-Shyong, Chang, Hsiu-Ju, Chien, Wu-Chien
Format: Article
Language:English
Subjects:
Adolescent
Adrenergic alpha-2 Receptor Antagonists - therapeutic use
Antipsychotic Agents - therapeutic use
Child
Cohort Studies
Comorbidity
Dopamine Antagonists - therapeutic use
Female
Humans
Male
Medication therapy
Neurodevelopmental Disorders - epidemiology
Psychiatric comorbidity
Research database
Retrospective Studies
Taiwan - epidemiology
Tics - drug therapy
Tics - etiology
Tourette syndrome (TS)
Tourette Syndrome - complications
Tourette Syndrome - drug therapy
Treatment outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tourette syndrome (TS) is often comorbid with attention deficit hyperactivity disorder, obsessive–compulsive disorder, and depression. Medications are the main treatment for TS. Relationships between TS medication therapy and psychiatric comorbidities remain unclear. This study explored the impacts of TS medication on the risk of psychiatric comorbidities using a nationally representative sample of TS in Taiwan. Data from National Health Insurance Research Database in Taiwan was used to identify 997,213 children and adolescents aged 6–18 years who had received a diagnosis of TS based on ICD-9-CM codes in 2000–2010. Cox’s proportional hazard regression analysis was conducted to estimate the risk of comorbidities among subjects with and without tic medication therapy. We found that in TS patients, a lower risk of psychiatric comorbidities occurred in the tic medication therapy group (p = 0.012) and the crude hazard ratio (HR) was 0.6 (95% confidence interval (CI) = 0.4–0.8, p 
ISSN:0387-7604
1872-7131
DOI:10.1016/j.braindev.2020.01.002